Anti-IgA isotype IgG Human ELISA

Cat. No.	Size	Price
RD199145100R	96 wells (1 kit)	$711

Technical Data

Type

Sandwich ELISA, HRP-labelled antibody

Applications

Serum, Plasma

Sample Requirements

5 μl/well

Shipping

At ambient temperature. Upon receipt, store the product at the temperature recommended below.

Storage/Expiration

Store the complete kit at 2–8°C. Under these conditions, the kit is stable until the expiration date (see label on the box).

Calibration Curve

Calibration Range

1.56–100 U/ml

Limit of Detection

0.71 U/ml

Intra-assay (Within-Run)

n = 8; CV = 4.8%

Inter-assay (Run-to-Run)

n = 5; CV = 5.3%

Spiking Recovery

102,00%

Dilution Linearity

91,00%

Crossreactivity

bovine Non-detectable
cat Non-detectable
dog Non-detectable
goat Non-detectable
hamster Non-detectable
horse Non-detectable
monkey Non-detectable
mouse Non-detectable
pig Non-detectable
rabbit Non-detectable
rat Non-detectable
sheep Non-detectable
chicken Not tested
human Yes

Note

The kits are CE-IVD certified and intended for professional use.

Summary

Features

European Union: for in vitro diagnostic use
Rest of the world: for research use only!
The total assay time is less than 3 hours.
The kit measures IgG anti-IgA antibodies in serum and plasma (EDTA, citrate, heparin).
Assay format is 96 wells.
Calibrator is serum based.
Quality Controls are human serum based. No animal sera are used.
Components of the kit are provided ready to use, concentrated or lyophilized.

Research topic

Autoimmunity, Immune Response, Infection and Inflammation, Immunology, Transplantation

Summary

Anti-IgA in the IgG class are specific IgG antibodies against immunoglobulin A. Patients with IgA deficiency often demonstrate circulating antibodies against IgA, which have been suggested to be associated with transfusion reactions. Anti-IgA antibodies occur in about 10% of patients with selective IgA deficiency (IgAD) and are detected approximately in the same percentage of patients with Common Variable Immunodeficiency (CVID). Patients with anti-IgA antibodies are at risk to develop an anaphylactoid reaction to substitution gamma globulin treatment, especially upon intravenous administration.

Product References (2)

References

Chovancova Z, Vlkova M, Litzman J, Lokaj J, Thon V. Antibody forming cells and plasmablasts in peripheral blood in CVID patients after vaccination. Vaccine. 2011 May 31;29(24):4142-50. doi: 10.1016/j.vaccine.2011.03.087. Epub 2011 Apr 5. PubMed PMID: 21473955. See more on PubMed
Schuster P, Sigmund K. Fixation probabilities for advantageous mutants: a note on multiplication and sampling. Math Biosci. 1989 Jul;95(1):37-51. doi: 10.1016/0025-5564(89)90050-3. PubMed PMID: 2520176. See more on PubMed

Summary References (16)

References to Anti-IgA IgG

Davenport RD, Mintz PD. Transfusion medicine. In Henry's Clinical Diagnosis. 2006;:707-708
de Albuquerque Campos R, Sato MN, da Silva Duarte AJ. IgG anti-IgA subclasses in common variable immunodeficiency and association with severe adverse reactions to intravenous immunoglobulin therapy. J Clin Immunol. 2000 Jan;20 (1):77-82
Hammarstrom L, Persson MA, Smith CI. Anti-IgA in selective IgA deficiency. In vitro effects and Ig subclass pattern of human anti-IgA. Scand J Immunol. 1983 Dec;18 (6):509-13
Horn J, Thon V, Bartonkova D, Salzer U, Warnatz K, Schlesier M, Peter HH, Grimbacher B. Anti-IgA antibodies in common variable immunodeficiency (CVID): diagnostic workup and therapeutic strategy. Clin Immunol. 2007 Feb;122 (2):156-62
Koskinen S, Hirvonen M, Tolo H. An enzyme immunoassay for the determination of anti-IgA antibodies using polyclonal human IgA. J Immunol Methods. 1995 Feb 13;179 (1):51-8
Limaye S, Walls RS, Riminton S. Safe and effective use of chromatographically purified intravenous immunoglobulin despite profound anti-IgA sensitization. Intern Med J. 2001 May-Jun;31 (4):256-7
Litzman J, Sevcikova I, Stikarovska D, Pikulova Z, Pazdirkova A, Lokaj J. IgA deficiency in Czech healthy individuals and selected patient groups. Int Arch Allergy Immunol. 2000 Oct;123 (2):177-80
Quartier P. [IgA deficiency]. Arch Pediatr. 2001 Jun;8 (6):629-33
Salama A, Schwind P, Schonhage K, Genth R, Cotting C, Hustinx H, Krieg R, Nydegger U, Aebischer I. Rapid detection of antibodies to immunoglobulin A molecules by using the particle gel immunoassay. Vox Sang. 2001 Jul;81 (1):45-8
Sandler SG, Eckrich R, Malamut D, Mallory D. Hemagglutination assays for the diagnosis and prevention of IgA anaphylactic transfusion reactions. Blood. 1994 Sep 15;84 (6):2031-5
Sandler SG, Zantek ND. Review: IgA anaphylactic transfusion reactions. Part II. Clinical diagnosis and bedside management. Immunohematology. 2004;20 (4):234-8
Sanz C, Freire C, Ordinas A, Pereira A. An enzyme-linked immunosorbent assay applicable to screen blood donors for IgA deficiency. Haematologica. 1999 Oct;84 (10):887-90
Steensma DP, Pruthi RK. Hematology. In Mayo Clinic Internal Medici. 2008;:427
Sundin U, Nava S, Hammarstrom L. Induction of unresponsiveness against IgA in IgA-deficient patients on subcutaneous immunoglobulin infusion therapy. Clin Exp Immunol. 1998 May;112 (2):341-6
Vassallo RR. Review: IgA anaphylactic transfusion reactions. Part I. Laboratory diagnosis, incidence, and supply of IgA-deficient products. Immunohematology. 2004;20 (4):226-33
Vorechovsky I, Webster AD, Plebani A, Hammarstrom L. Genetic linkage of IgA deficiency to the major histocompatibility complex: evidence for allele segregation distortion, parent-of-origin penetrance differences, and the role of anti-IgA antibodies in disease predisposition. Am J Hum Genet. 1999 Apr;64 (4):1096-109

Docs

Find documents for the lot

Example Instructions for Use (RUO)

Safety Information (RUO)

MSDS (RUO)
MSDS (RUO)
MSDS (RUO)

Product Brochure

CE IVD Assays